Patent SG-11201907422R-A (SG)
Title: Anti-tau antibodies and methods of use thereof
Inventor: CHEN XIAOCHENG
IPC: A61P25/28
Filed: 2018-02-15
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 23 August 2018 (23.08.2018) WIP0 I PCT 0111111010 0111 °nolo III OH VIII VIII ioluo oimIE (10) International Publication Number WO 2018/152359 Al W O 20 18/ 15 235 9 Al (51) International Patent Classification: C07K 16/18 (2006.01) A61P 25/28 (2006.01) (21) International Application Number: PCT/US2018/018415 (22) International Filing Date: 15 February 2018 (15.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/460,642 17 February 2017 (17.02.2017) US 62/583,400 08 November 2017 (08.11.2017) US (71) Applicant: DENALI THERAPEUTICS INC. [US/US]; 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US). (72) Inventors: CHEN, Xiaocheng; c/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francis- co, California 94080 (US). DENNIS, Mark S.; c/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US). KANE, Lesley Ann; c/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francisco, CA 94080 (US). KIM, Do Jin; c/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US). LEW- COCK, Joseph W.; c/o Denali Therapeutics Inc., 151 Oys- ter Point Blvd., 2nd Floor, South San Francisco, Califor- nia 94080 (US). PODA, Suresh; c/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Fran- cisco, California 94080 (US). RAKHIT, Rishi; c/o De- nali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US). SHUKLA, Rinkan; c/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US). SILVERMAN, Adam P.; c/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francis- co, California 94080 (US). (74) Agent: FLANAGAN, Lisa Dornbach et al.; Kilpatrick Townsend & Stockton LLP, Mailstop: IP Docketing - 22, 1100 Peachtree Street, Suite 2800, Atlanta, Georgia 30309 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (54) Title: ANTI-TAU ANTIBODIES AND METHODS OF USE THEREOF (57) : In one aspect, antibodies that specifically bind to a human Tau protein are provided. In some embodiments, an anti-Tau antibody recognizes an epitope within residues 111-125 of full-length human Tau, an epitope within residues 251-270 and/or residues 346-360 of full-length human Tau, or an epitope within residues 186-205 of full-length human Tau. In some embodiments, an anti-Tau antibody specifically binds to phosphorylated human Tau, unphosphorylated human Tau, and/or multiple splice isoforms of human Tau. An anti-Tau antibody disclosed herein may also include one or two modified Fc polypeptides.